OpenEvidence, 'ChatGPT for doctors', doubles its valuation to $12 billion
A startup widely known as “ChatGPT for doctors” raised a new round of funding that values the company at $12…
markets
Another Alliance Between Healthcare and AI Indicates Why Pharma Stocks Could Make a Comeback
Bristol Myers Squibb and Microsoft's new partnership aimed at accelerating the early detection of lung cancer marks the latest way…
Boeing aircraft deliveries are the highest in years. Now it's increasing
A Boeing Co. 737 Max aircraft at the company's manufacturing facility in Renton, Washington, U.S., Thursday, Nov. 20, 2025. David…
Why airline class wars will escalate in 2026
Planes line the runway at LaGuardia Airport on November 10, 2025 in New York City. Spencer Platt | Getty Images…
Airlines eliminate change fees ahead of winter storm
A traveler near a departure board at Newark Liberty International Airport (EWR) in Newark, New Jersey, U.S., Monday, Nov. 24,…
Eli Lilly investors shouldn't worry that rival Novo Nordisk has the first anti-obesity pill on sale
Jim Cramer says not to worry about Novo Nordisk's lead over Club that has Eli Lilly in the obesity pill…
Shares of Novo Nordisk, maker of Wegovy, rise after approval of GLP-1 pill
Novo Nordisk shares rose more than 7% on Tuesday after the Wegovy maker secured approval for its GLP-1 pill, a…
Trump confirms possible drug reclassification, but stocks fall
Bill Schmitt Jr. (C) joins cannabis reform protesters outside the White House to call on US President Joe Biden “to…
Why Wall Street and Jim Cramer Think Danaher Stock Is 'Ready to Play'
Danaher is finally turning the corner. CNBC's Jim Cramer sees it. Wall Street does it too. Life sciences stocks are…
Rivian's AI and autonomy impress, but not enough to offset concerns about electric vehicles
Rivian CEO RJ Scaringe at the company's first “Autonomy and AI Day” on December 11, 2025 in Palo Alto, California.…